Investigators have found evidence of reduced T cell immunity during COVID-19 illness followed by T cell recovery in kidney transplant recipients. Insufficient immunity appears to occur despite initial reduction of antirejection medications in these patients.
Most centers have empirically reduced anti-rejection immunosuppression in kidney transplant recipients with COVID-19 due to concerns that immunosuppressant use would hinder anti-COVID-19 immunity, Madhav C. Menon, MBBS, of Yale University in New Haven, Connecticut, and colleagues explained in the Journal of the American Society of Nephrology. Read the full story in Reanl & Urology News.